{"ticker": {"uuid": "eba7ca04-c418-4a53-850e-bf73cfe64a6f", "symbol": "BYSI", "name": "BeyondSpring Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "BeyondSpring (BYSI) Q1 2026 Earnings: EPS Loss of -$0.05 Amid No Revenue and Stock Decline - Guidance vs Actual", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxOMDN4MkllbUVLdGlNWVNsdGpmSW4tTVBVT2s3N2pZUzZQMHB0cXF3VEJ3RnlrZzdkS2ljdVYxZU5sMU14ZzMzQ2tCS0dmSHAwdGFic1JUdU1FUnZzRnF6U0FFNVI4R1lqU01BTVJ0UHVla0xnX25UdXF6b1F2MVVJb1hJUGpXckh3dmNYcUVzLTdLNjNzeENJZTJQTEVKYnlSWlFsNldma2ZUUk5XMHE0UXd5THpTTktGeTJ1eWd2ckVXemlPT3hacFdwczk?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-07-07T23:44:44+00:00", "published_display": "07 Jul 2026 23:44", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 BeyondSpring Inc For: 6 July By Investing.com", "summary": "This article provides an announcement regarding a Form 4 filing for BeyondSpring Inc. on July 6. It briefly mentions the company's stock symbol BYSI and includes standard market data alongside the short notice. The core content is the notification of the regulatory filing, withou", "url": "https://ng.investing.com/news/stock-market-news/form-4-beyondspring-inc-for-6-july-93CH-2587347", "source_name": "Investing.com Nigeria", "published_at": "2026-07-06T18:16:00", "published_display": "06 Jul 2026 18:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring (BYSI) CEO Qiu Min reports direct holding of 2,498 Ordinary Shares", "summary": "BeyondSpring Inc. CEO Qiu Min has reported a direct ownership of 2,498 Ordinary Shares in a recent Form 3 filing. This disclosure serves as an initial statement of beneficial ownership, establishing a baseline for the CEO's holdings rather than indicating a new buy or sell transa", "url": "https://www.stocktitan.net/sec-filings/BYSI/form-3-beyond-spring-inc-initial-statement-of-beneficial-ownership-2bc730fefc98.html", "source_name": "Stock Titan", "published_at": "2026-07-06T17:39:24", "published_display": "06 Jul 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring (BYSI) director receives 100,000 stock options grant", "summary": "BeyondSpring Inc. director Majeti Jiangwen was granted 100,000 stock options to purchase ordinary shares, with an exercise price of $1.75 per share and an expiration date of July 1, 2036. The options will vest in four equal 25% installments annually, contingent on Jiangwen's cont", "url": "https://www.stocktitan.net/sec-filings/BYSI/form-4-beyond-spring-inc-insider-trading-activity-669f205195a7.html", "source_name": "Stock Titan", "published_at": "2026-07-06T17:39:24", "published_display": "06 Jul 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring (BYSI) CEO awarded 100,000 stock options at $1.75 strike price", "summary": "BeyondSpring Inc. CEO Qiu Min has been granted 100,000 stock options with a strike price of $1.75 per share, expiring on July 1, 2036. These options, part of her compensation under the 2017 Omnibus Incentive Plan, will vest in four equal 25% installments annually, contingent on h", "url": "https://www.stocktitan.net/sec-filings/BYSI/form-4-beyond-spring-inc-insider-trading-activity-c53d93ff9ffd.html", "source_name": "Stock Titan", "published_at": "2026-07-06T17:39:23", "published_display": "06 Jul 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring (BYSI) CFO Li Na submits initial Form 3 ownership filing", "summary": "BeyondSpring Inc. (BYSI) CFO Li Na has filed her initial Form 3, which is a statement of beneficial ownership, with the SEC. This filing serves as the first formal record of her holdings in the company as an officer, but it reports no transactions, acquisitions, or derivative pos", "url": "https://www.stocktitan.net/sec-filings/BYSI/form-3-beyond-spring-inc-initial-statement-of-beneficial-ownership-36455879d7e1.html", "source_name": "Stock Titan", "published_at": "2026-07-06T16:40:34", "published_display": "06 Jul 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring (BYSI) finalizes CEO Min Qiu salary, bonus and option grant", "summary": "BeyondSpring Inc. (BYSI) has finalized the employment terms for its new CEO, Min Qiu, as detailed in an amended 8-K filing. His compensation package includes an annual base salary of $100,000, eligibility for an annual bonus targeting 30% of his base salary, and options to purcha", "url": "https://www.stocktitan.net/sec-filings/BYSI/8-k-a-beyond-spring-inc-amends-material-event-report-de6e0e573568.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:39:51", "published_display": "29 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring (BYSI) Q1 2026 Earnings: Net Loss of -$0.05 Per Share as Clinical Programs Advance - Revenue Guidance Range", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxOcl9Gcl9oQW5OLUhHTmtkaVcwd1ZRQnpONGw2c3VOb2dfM2FUb3dOb2k1OFlaWktVT3JrTm9HSmwtdjVYNVBxNWpCN3RSM21QcTlCeWJZZ1p5UUVvNlA5dEVyeUh3Q1Z5NlhlWjdSOGN2MTQ5Y0xhRkk3eUlZbm1sdlExeTcwdmdSbTFGc21VZ010VGw4S3ZmU1lUMUJhS2dlLWlySWxqTU4zM1lMVVB2Z3EtTFN0M3h5UUE2QU56MUJOWnRCUHQyemhabmJ4NzhyUzZINQ?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of BeyondSpring, Inc. \u2013 NASDAQ:BYSI", "summary": "This article mentions BeyondSpring, Inc. (NASDAQ: BYSI) and briefly touches upon its financial metric, \"Price to sales forward.\" The content provided is minimal and appears to be an unpopulated or partial financial data page from TradingView, stating \"No trades\" and \"Period Value", "url": "https://www.tradingview.com/symbols/NASDAQ-BYSI/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T11:40:35", "published_display": "28 Jun 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of BeyondSpring, Inc. \u2013 NASDAQ:BYSI", "summary": "This article provides a financial overview of BeyondSpring, Inc. (NASDAQ: BYSI) focusing on its enterprise value to EBITDA forward metric. The content indicates that the company's financial data is available through TradingView, which sources information from ICE Data Services an", "url": "https://www.tradingview.com/symbols/NASDAQ-BYSI/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T23:10:46", "published_display": "27 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of BeyondSpring, Inc. \u2013 NASDAQ:BYSI", "summary": "The article provides a financial metric, \"Enterprise value to revenue forward,\" for BeyondSpring, Inc. (NASDAQ: BYSI). It is presented on TradingView's platform, indicating that the market for this stock is currently closed with no active trades. The information includes standard", "url": "https://www.tradingview.com/symbols/NASDAQ-BYSI/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T10:10:24", "published_display": "27 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of BeyondSpring, Inc. \u2013 NASDAQ:BYSI", "summary": "This article provides financial information for BeyondSpring, Inc. under its NASDAQ ticker BYSI, specifically focusing on its Price to Book Forward metric. It appears to be a stub or a data-focused page from TradingView, lacking detailed analysis but presenting the company's fina", "url": "https://www.tradingview.com/symbols/NASDAQ-BYSI/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T07:40:11", "published_display": "27 Jun 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring Inc. Actuals & Estimates (NASDAQ:BYSI)", "summary": "This article provides financial actuals and estimates for BeyondSpring Inc. (NASDAQ:BYSI), including its current stock price, historical performance, market capitalization, and upcoming earnings report date. It also addresses common questions about BYSI's stock, such as volatilit", "url": "https://www.tradingview.com/symbols/NASDAQ-BYSI/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T16:41:02", "published_display": "25 Jun 2026 16:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring Inc. (BYSI) Slips 2.48%: Stock Tests Key Support at $1.49 - Cumulative Volume", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPbFEyelNoWExtdV9KZUphNGVSb3N0aUo0bXN4RE9Ec3MzZW00cjlSVGtvcDJwUWxCem9OY2F2THEtTlQxbU9fbGpnZk1nX0ZEN0tFLWdVQXgzdEZFR0pOajUwa0M2S3BBbnNwTEY3QWsyLUVSVmNnNjd6dm1pSURqemFDWUlCNjRIMDFCbVpfaVE0VGRCR0xBeDB0ODVHNHEzZHJjOEJCaDNiSkx2NlE?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring Inc. (BYSI) Q1 2026 Earnings: Narrowing Losses Amid Strategic Clinical Progress - Analyst Drop Coverage", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxOdDJENG1JbjYyaGR6bThMbnJKajNKcGFTODFTdDJGajNqYi1OZ3Y3bzdpc1ZtWXdKZWdkdnZfUzlRYUpMTmhMMlVkdHBxc3I4V2JVV09KX0kwdzFWVW5acGxHWmVYR2d6bnNkTUwyeHFiWER6SmlfaThYVnBDRFJ1Y296Zlk4WW1JRzEzR09vT2ZKNWV6SXZUV1hXQUhwUm5Wb191Q002RHlITkZVYUZTcUNfbUVETmtlV25vRlhDZlNCQmJDS0RFdk1ZOWFjdw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-21T07:00:00+00:00", "published_display": "21 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beyondspring Inc (BYSI) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Beyondspring Inc (BYSI), listing major individual and institutional holders, as well as the proportion held by various shareholder types. It provides a historical overview of institutional shareholding from Q4 2023 to Q1 2026, sho", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bysi/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T05:39:21", "published_display": "18 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beyondspring Inc (BYSI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey focuses on Beyondspring Inc (BYSI) and attempts to provide a revenue breakdown by business segments and regions. However, it explicitly states that the relevant financial data has not been disclosed by the company yet, meaning no specific figures or i", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bysi/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T05:39:20", "published_display": "18 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beyondspring Inc (BYSI) Institutional Confidence", "summary": "Beyondspring Inc (BYSI) has an institutional shareholding score of 3.00, placing it 193rd out of 389 in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 14.61%, which is a decrease of 9.34% quarter-over-quarter. James Simons is the large", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bysi/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T04:46:46", "published_display": "18 Jun 2026 04:46", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beyondspring Inc (BYSI) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides a historical overview of Beyondspring Inc (BYSI) regarding its dividends and stock splits. It explicitly states that the company has not distributed any dividends over the past five years and has no recorded stock split data. The page also includes current s", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bysi/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T03:39:21", "published_display": "18 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beyondspring Inc (BYSI) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Beyondspring Inc (BYSI), noting that no earnings forecast score is currently available for the company, contrasting with the Biotechnology & Medical Research industry's average score of 8.13. It also states that relevant financial fo", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bysi/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T09:10:13", "published_display": "17 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beyondspring Inc (BYSI) Valuation: PE, PB & Fair Value Analysis", "summary": "Beyondspring Inc (BYSI) currently holds a valuation score of 8.38, ranking 140th out of 388 in the Biotechnology & Medical Research industry. The company's P/E ratio is -8.49, which is significantly below its recent high but above its recent low. Key valuation metrics such as P/B", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bysi/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T09:10:13", "published_display": "17 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beyondspring Inc (BYSI) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Beyondspring Inc (BYSI), detailing its price momentum score of 9.05 and positioning within the Biotechnology & Medical Research industry. It highlights the stock's trading range between resistance at $1.85 and support at $1.26, indica", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bysi/technical", "source_name": "TradingKey", "published_at": "2026-06-17T09:10:13", "published_display": "17 Jun 2026 09:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring (NASDAQ: BYSI) overhauls leadership to drive DUBLIN-4 lung cancer program", "summary": "BeyondSpring Inc. (NASDAQ: BYSI) announced a major leadership transition aimed at advancing its DUBLIN-4 confirmatory Phase 3 trial for Plinabulin in non-small cell lung cancer. Founder and CEO Dr. Lan Huang will step down as CEO but remain Chair of the Board, focusing her operat", "url": "https://www.stocktitan.net/sec-filings/BYSI/8-k-beyond-spring-inc-reports-material-event-e0cfd7a95d7c.html", "source_name": "Stock Titan", "published_at": "2026-06-08T15:10:06", "published_display": "08 Jun 2026 15:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring Announces Major Leadership Transition and New CEO", "summary": "BeyondSpring (BYSI) has announced a significant leadership change, effective July 1, 2026. Founder Dr. Lan Huang will step down as CEO but remain as chair, focusing on SEED Therapeutics, while Min Qiu will take over as the new CEO. The company also appointed Dr. Jiangwen Majeti a", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/2323718/beyondspring-announces-major-leadership-transition-and-new-ceo/", "source_name": "The Globe and Mail", "published_at": "2026-06-08T15:10:06", "published_display": "08 Jun 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BYSI - BeyondSpring Inc Stock Price and Quote", "summary": "This page provides a detailed financial overview and news updates for BeyondSpring Inc. (BYSI), a biotechnology company focused on immuno-oncology cancer therapies. It includes real-time stock quotes, key financial metrics, analyst ratings history, and a compilation of recent pre", "url": "https://finviz.com/stock?t=BYSI", "source_name": "Finviz", "published_at": "2026-06-04T23:40:04", "published_display": "04 Jun 2026 23:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring Elevates Min Qiu to CEO, Names Na Li CFO in Leadership Transition", "summary": "BeyondSpring Inc. has announced a significant leadership transition, appointing Min Qiu as CEO and Na Li as CFO, effective July 1, 2026. Founder Dr. Lan Huang will remain Chairman while focusing on SEED Therapeutics. This restructuring aims to align management with the operationa", "url": "https://www.citybiz.co/article/856096/beyondspring-elevates-min-qiu-to-ceo-names-na-li-cfo-in-leadership-transition/", "source_name": "citybiz", "published_at": "2026-06-04T16:42:27", "published_display": "04 Jun 2026 16:42", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring names new CEO, CFO as founder shifts to chairman role By Investing.com", "summary": "BeyondSpring Inc. has announced a leadership transition effective July 1, 2026, with Min Qiu appointed as CEO and Na Li as CFO. Founder Dr. Lan Huang will move to a Chairman role, while Dr. Jiangwen Majeti becomes Vice Chairman. The company is advancing its Phase 3 trial for Plin", "url": "https://m.za.investing.com/news/stock-market-news/beyondspring-names-new-ceo-cfo-as-founder-shifts-to-chairman-role-93CH-4314171?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-06-04T16:42:27", "published_display": "04 Jun 2026 16:42", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring Inc. Appoints Na Li as Chief Financial Officer, Effective July 1, 2026", "summary": "BeyondSpring Inc. has appointed Ms. Na Li as its new Chief Financial Officer, effective July 1, 2026. Ms. Li brings over two decades of finance leadership experience from the pharmaceutical, biotechnology, and public-company sectors, including previous CFO roles. Her expertise in", "url": "https://www.marketscreener.com/news/beyondspring-inc-appoints-na-li-as-chief-financial-officer-effective-july-1-2026-ce7f5ddcd18cf725", "source_name": "www.marketscreener.com", "published_at": "2026-06-04T13:42:27", "published_display": "04 Jun 2026 13:42", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value", "summary": "BeyondSpring Inc. has announced a significant leadership transition effective July 1, 2026, aimed at focusing on the DUBLIN-4 Phase 3 program for Plinabulin. Dr. Lan Huang will remain Chairman of BeyondSpring while also leading SEED Therapeutics, and Min Qiu has been appointed CE", "url": "https://www.globenewswire.com/news-release/2026/06/04/3306631/0/en/beyondspring-announces-leadership-transition-to-deliver-focused-execution-on-its-confirmatory-dublin-4-program-and-long-term-value.html", "source_name": "GlobeNewswire", "published_at": "2026-06-04T07:00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026", "summary": "BeyondSpring announced updated efficacy and safety data from a Phase 2 study of pembrolizumab plus Plinabulin and docetaxel in metastatic NSCLC patients who progressed after first-line immune checkpoint inhibitor therapy. The study, presented at ASCO 2026, demonstrated durable cl", "url": "https://www.manilatimes.net/2026/06/02/tmt-newswire/globenewswire/beyondspring-presents-the-latest-update-of-a-phase-2-study-demonstrating-durable-clinical-benefit-of-pembrolizumab-plus-plinabulindocetaxel-in-metastatic-nsclc-after-progression-on-first-line-immune-checkpoint-inhibitor-therapy-at-asco-2026/2356639/amp", "source_name": "The Manila Times", "published_at": "2026-06-03T10:39:39", "published_display": "03 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring Presents the Latest Update of a Phase 2 Study", "summary": "BeyondSpring Inc. announced updated efficacy and safety data from an investigator-initiated Phase 2 study of pembrolizumab plus Plinabulin and docetaxel for metastatic non-small cell lung cancer (NSCLC) patients who progressed after first-line immune checkpoint inhibitor therapy.", "url": "https://www.globenewswire.com/news-release/2026/06/02/3304984/0/en/beyondspring-presents-the-latest-update-of-a-phase-2-study-demonstrating-durable-clinical-benefit-of-pembrolizumab-plus-plinabulin-docetaxel-in-metastatic-nsclc-after-progression-o.html", "source_name": "GlobeNewswire", "published_at": "2026-06-02T10:40:37", "published_display": "02 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring (BYSI) Faces Selling Pressure: Support Levels Tested After 2.33% Decline - Point of Control", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPc1JKRnpMNndtbWJXSXY2QUQ0b25weVhjeUc5TmNNLWFtbXh6STdGTTJsSW5jaWNyWkxKUmhnclV4U3pkdHhKQ3dOa29KTnJNMHJzeV96YXIxSFFLTGQ0NjBmTXN2aUxuNnZnV3VrYk5HVGhNTlNYdTRvM1l2TVRLT0F5VDJESERLcXpKOFlDalJmMVlDMkxheUlsTVV0NnhmR19DcVUyZGR4aXpCdUphSWs5MEkyNW1oZ05jdl93cW0zRF9kZnR6S1JWWnY?oc=5", "source_name": "B\u00f6l\u00fcm Sonu Canavar\u0131", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring (BYSI) Faces Selling Pressure: Support Levels Tested After 2.33% Decline - Insider Buying Alerts", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOZ3BhcWVvR0FxRGFGQ2M0QmVNc2JIWTZDcEduRzFuWWN6N1ozS0gtXzZJQWlVeTJkQ1ZTV1pkWHFHbDFzN3llR0dNaGxDdjMwLWZmbWh3T3lub3ZLeHBGQzIxUDBfN3AyT2xnMkg1WUtMb1FVNjVXcVJuUnVuOXBpOWVsc3VManZsVVNHaUY1eC1haS1UdjRGUHN1WXhxbkVFQWdwUXhBSEhLMjlsQnJOMWlFRm9KMDFmUXM2eEszVm9Hd3J0Z3c?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting", "summary": "BeyondSpring Inc. announced an upcoming poster presentation at the 2026 ASCO Annual Meeting. The presentation will detail Study 303, an investigator-initiated Phase 2 study supported by Merck and BeyondSpring, focusing on a triple combination therapy for metastatic non-small cell", "url": "https://www.globenewswire.com/news-release/2026/05/18/3296480/0/en/beyondspring-announces-poster-presentation-at-2026-asco-annual-meeting.html", "source_name": "GlobeNewswire", "published_at": "2026-05-18T11:10:36", "published_display": "18 May 2026 11:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "BeyondSpring shares rise after narrower quarterly loss and pipeline advances (BYSI)", "summary": "", "url": "https://finance.yahoo.com/m/2b6d08a5-dc2e-3913-ac65-dadae08f7898/beyondspring-shares-rise.html", "source_name": "InvestorsHub", "published_at": "2026-05-13T13:29:56+00:00", "published_display": "13 May 2026 13:29", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update", "summary": "", "url": "https://finance.yahoo.com/news/beyondspring-reports-first-quarter-2026-110000960.html", "source_name": "GlobeNewswire", "published_at": "2026-05-13T11:00:00+00:00", "published_display": "13 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/beyondspring-reports-compelling-data-plinabulin-110000913.html", "source_name": "GlobeNewswire", "published_at": "2026-04-22T11:00:00+00:00", "published_display": "22 Apr 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "BeyondSpring Inc. Confirms Phase 3 Overall Survival Benefit for Plinabulin in NSCLC and Plans DUBLIN-4 Study", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxOUk1BMjRjZVd5LXc0WG1LZkhiNFNKNlFDS1UzYXc4eXhST012RFB6MWZscWdUQmFxSVM3WF8yT0RuSno4Y1dnLUl3d1pEaUhUc19hQTJGSERoamQ1OS1MYU40UmJQeU9Nd1Z6a0Z1NVQ3N3lOZWpaRmZxNE9UMzlkVFZySWNURXVqTHFHSVRYUTFGLVUzelFqcXd2WTF3MHdWY24zX3pvZnp2YWpCSFctc3E0bHROMzZndXNGS2VtY0gzSGMydUlUQVdRbHNyNzNOckhfa1RGYUM?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring (BYSI) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE9SNWZhalJrT1BFTHpfeVd6QVR5ZFNJblR1QnFnTHFYSGNSczlWTTA2QXhoaWh5cU1mQ25rVjZTY2pQaXhfRUcwcTBWR2xySjNMR2ktOFU0RTdvUQ?oc=5", "source_name": "MarketBeat", "published_at": "2017-04-01T16:56:20+00:00", "published_display": "01 Apr 2017 16:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "BeyondSpring (BYSI) Q1 2026 Earnings: EPS Loss of -$0.05 Amid No Revenue and Stock Decline - Guidance vs Actual", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxOMDN4MkllbUVLdGlNWVNsdGpmSW4tTVBVT2s3N2pZUzZQMHB0cXF3VEJ3RnlrZzdkS2ljdVYxZU5sMU14ZzMzQ2tCS0dmSHAwdGFic1JUdU1FUnZzRnF6U0FFNVI4R1lqU01BTVJ0UHVla0xnX25UdXF6b1F2MVVJb1hJUGpXckh3dmNYcUVzLTdLNjNzeENJZTJQTEVKYnlSWlFsNldma2ZUUk5XMHE0UXd5THpTTktGeTJ1eWd2ckVXemlPT3hacFdwczk?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-07-07T23:44:44+00:00", "published_display": "07 Jul 2026 23:44", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 BeyondSpring Inc For: 6 July By Investing.com", "summary": "This article provides an announcement regarding a Form 4 filing for BeyondSpring Inc. on July 6. It briefly mentions the company's stock symbol BYSI and includes standard market data alongside the short notice. The core content is the notification of the regulatory filing, withou", "url": "https://ng.investing.com/news/stock-market-news/form-4-beyondspring-inc-for-6-july-93CH-2587347", "source_name": "Investing.com Nigeria", "published_at": "2026-07-06T18:16:00", "published_display": "06 Jul 2026 18:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring (BYSI) CEO Qiu Min reports direct holding of 2,498 Ordinary Shares", "summary": "BeyondSpring Inc. CEO Qiu Min has reported a direct ownership of 2,498 Ordinary Shares in a recent Form 3 filing. This disclosure serves as an initial statement of beneficial ownership, establishing a baseline for the CEO's holdings rather than indicating a new buy or sell transa", "url": "https://www.stocktitan.net/sec-filings/BYSI/form-3-beyond-spring-inc-initial-statement-of-beneficial-ownership-2bc730fefc98.html", "source_name": "Stock Titan", "published_at": "2026-07-06T17:39:24", "published_display": "06 Jul 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring (BYSI) director receives 100,000 stock options grant", "summary": "BeyondSpring Inc. director Majeti Jiangwen was granted 100,000 stock options to purchase ordinary shares, with an exercise price of $1.75 per share and an expiration date of July 1, 2036. The options will vest in four equal 25% installments annually, contingent on Jiangwen's cont", "url": "https://www.stocktitan.net/sec-filings/BYSI/form-4-beyond-spring-inc-insider-trading-activity-669f205195a7.html", "source_name": "Stock Titan", "published_at": "2026-07-06T17:39:24", "published_display": "06 Jul 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring (BYSI) CEO awarded 100,000 stock options at $1.75 strike price", "summary": "BeyondSpring Inc. CEO Qiu Min has been granted 100,000 stock options with a strike price of $1.75 per share, expiring on July 1, 2036. These options, part of her compensation under the 2017 Omnibus Incentive Plan, will vest in four equal 25% installments annually, contingent on h", "url": "https://www.stocktitan.net/sec-filings/BYSI/form-4-beyond-spring-inc-insider-trading-activity-c53d93ff9ffd.html", "source_name": "Stock Titan", "published_at": "2026-07-06T17:39:23", "published_display": "06 Jul 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring (BYSI) CFO Li Na submits initial Form 3 ownership filing", "summary": "BeyondSpring Inc. (BYSI) CFO Li Na has filed her initial Form 3, which is a statement of beneficial ownership, with the SEC. This filing serves as the first formal record of her holdings in the company as an officer, but it reports no transactions, acquisitions, or derivative pos", "url": "https://www.stocktitan.net/sec-filings/BYSI/form-3-beyond-spring-inc-initial-statement-of-beneficial-ownership-36455879d7e1.html", "source_name": "Stock Titan", "published_at": "2026-07-06T16:40:34", "published_display": "06 Jul 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring (BYSI) finalizes CEO Min Qiu salary, bonus and option grant", "summary": "BeyondSpring Inc. (BYSI) has finalized the employment terms for its new CEO, Min Qiu, as detailed in an amended 8-K filing. His compensation package includes an annual base salary of $100,000, eligibility for an annual bonus targeting 30% of his base salary, and options to purcha", "url": "https://www.stocktitan.net/sec-filings/BYSI/8-k-a-beyond-spring-inc-amends-material-event-report-de6e0e573568.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:39:51", "published_display": "29 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring (BYSI) Q1 2026 Earnings: Net Loss of -$0.05 Per Share as Clinical Programs Advance - Revenue Guidance Range", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxOcl9Gcl9oQW5OLUhHTmtkaVcwd1ZRQnpONGw2c3VOb2dfM2FUb3dOb2k1OFlaWktVT3JrTm9HSmwtdjVYNVBxNWpCN3RSM21QcTlCeWJZZ1p5UUVvNlA5dEVyeUh3Q1Z5NlhlWjdSOGN2MTQ5Y0xhRkk3eUlZbm1sdlExeTcwdmdSbTFGc21VZ010VGw4S3ZmU1lUMUJhS2dlLWlySWxqTU4zM1lMVVB2Z3EtTFN0M3h5UUE2QU56MUJOWnRCUHQyemhabmJ4NzhyUzZINQ?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of BeyondSpring, Inc. \u2013 NASDAQ:BYSI", "summary": "This article mentions BeyondSpring, Inc. (NASDAQ: BYSI) and briefly touches upon its financial metric, \"Price to sales forward.\" The content provided is minimal and appears to be an unpopulated or partial financial data page from TradingView, stating \"No trades\" and \"Period Value", "url": "https://www.tradingview.com/symbols/NASDAQ-BYSI/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T11:40:35", "published_display": "28 Jun 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of BeyondSpring, Inc. \u2013 NASDAQ:BYSI", "summary": "This article provides a financial overview of BeyondSpring, Inc. (NASDAQ: BYSI) focusing on its enterprise value to EBITDA forward metric. The content indicates that the company's financial data is available through TradingView, which sources information from ICE Data Services an", "url": "https://www.tradingview.com/symbols/NASDAQ-BYSI/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T23:10:46", "published_display": "27 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of BeyondSpring, Inc. \u2013 NASDAQ:BYSI", "summary": "The article provides a financial metric, \"Enterprise value to revenue forward,\" for BeyondSpring, Inc. (NASDAQ: BYSI). It is presented on TradingView's platform, indicating that the market for this stock is currently closed with no active trades. The information includes standard", "url": "https://www.tradingview.com/symbols/NASDAQ-BYSI/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T10:10:24", "published_display": "27 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of BeyondSpring, Inc. \u2013 NASDAQ:BYSI", "summary": "This article provides financial information for BeyondSpring, Inc. under its NASDAQ ticker BYSI, specifically focusing on its Price to Book Forward metric. It appears to be a stub or a data-focused page from TradingView, lacking detailed analysis but presenting the company's fina", "url": "https://www.tradingview.com/symbols/NASDAQ-BYSI/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T07:40:11", "published_display": "27 Jun 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring Inc. Actuals & Estimates (NASDAQ:BYSI)", "summary": "This article provides financial actuals and estimates for BeyondSpring Inc. (NASDAQ:BYSI), including its current stock price, historical performance, market capitalization, and upcoming earnings report date. It also addresses common questions about BYSI's stock, such as volatilit", "url": "https://www.tradingview.com/symbols/NASDAQ-BYSI/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T16:41:02", "published_display": "25 Jun 2026 16:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring Inc. (BYSI) Slips 2.48%: Stock Tests Key Support at $1.49 - Cumulative Volume", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPbFEyelNoWExtdV9KZUphNGVSb3N0aUo0bXN4RE9Ec3MzZW00cjlSVGtvcDJwUWxCem9OY2F2THEtTlQxbU9fbGpnZk1nX0ZEN0tFLWdVQXgzdEZFR0pOajUwa0M2S3BBbnNwTEY3QWsyLUVSVmNnNjd6dm1pSURqemFDWUlCNjRIMDFCbVpfaVE0VGRCR0xBeDB0ODVHNHEzZHJjOEJCaDNiSkx2NlE?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring Inc. (BYSI) Q1 2026 Earnings: Narrowing Losses Amid Strategic Clinical Progress - Analyst Drop Coverage", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxOdDJENG1JbjYyaGR6bThMbnJKajNKcGFTODFTdDJGajNqYi1OZ3Y3bzdpc1ZtWXdKZWdkdnZfUzlRYUpMTmhMMlVkdHBxc3I4V2JVV09KX0kwdzFWVW5acGxHWmVYR2d6bnNkTUwyeHFiWER6SmlfaThYVnBDRFJ1Y296Zlk4WW1JRzEzR09vT2ZKNWV6SXZUV1hXQUhwUm5Wb191Q002RHlITkZVYUZTcUNfbUVETmtlV25vRlhDZlNCQmJDS0RFdk1ZOWFjdw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-21T07:00:00+00:00", "published_display": "21 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beyondspring Inc (BYSI) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Beyondspring Inc (BYSI), listing major individual and institutional holders, as well as the proportion held by various shareholder types. It provides a historical overview of institutional shareholding from Q4 2023 to Q1 2026, sho", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bysi/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T05:39:21", "published_display": "18 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beyondspring Inc (BYSI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey focuses on Beyondspring Inc (BYSI) and attempts to provide a revenue breakdown by business segments and regions. However, it explicitly states that the relevant financial data has not been disclosed by the company yet, meaning no specific figures or i", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bysi/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T05:39:20", "published_display": "18 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beyondspring Inc (BYSI) Institutional Confidence", "summary": "Beyondspring Inc (BYSI) has an institutional shareholding score of 3.00, placing it 193rd out of 389 in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 14.61%, which is a decrease of 9.34% quarter-over-quarter. James Simons is the large", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bysi/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T04:46:46", "published_display": "18 Jun 2026 04:46", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beyondspring Inc (BYSI) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides a historical overview of Beyondspring Inc (BYSI) regarding its dividends and stock splits. It explicitly states that the company has not distributed any dividends over the past five years and has no recorded stock split data. The page also includes current s", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bysi/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T03:39:21", "published_display": "18 Jun 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beyondspring Inc (BYSI) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Beyondspring Inc (BYSI), noting that no earnings forecast score is currently available for the company, contrasting with the Biotechnology & Medical Research industry's average score of 8.13. It also states that relevant financial fo", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bysi/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T09:10:13", "published_display": "17 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beyondspring Inc (BYSI) Valuation: PE, PB & Fair Value Analysis", "summary": "Beyondspring Inc (BYSI) currently holds a valuation score of 8.38, ranking 140th out of 388 in the Biotechnology & Medical Research industry. The company's P/E ratio is -8.49, which is significantly below its recent high but above its recent low. Key valuation metrics such as P/B", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bysi/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-17T09:10:13", "published_display": "17 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beyondspring Inc (BYSI) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Beyondspring Inc (BYSI), detailing its price momentum score of 9.05 and positioning within the Biotechnology & Medical Research industry. It highlights the stock's trading range between resistance at $1.85 and support at $1.26, indica", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bysi/technical", "source_name": "TradingKey", "published_at": "2026-06-17T09:10:13", "published_display": "17 Jun 2026 09:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring (NASDAQ: BYSI) overhauls leadership to drive DUBLIN-4 lung cancer program", "summary": "BeyondSpring Inc. (NASDAQ: BYSI) announced a major leadership transition aimed at advancing its DUBLIN-4 confirmatory Phase 3 trial for Plinabulin in non-small cell lung cancer. Founder and CEO Dr. Lan Huang will step down as CEO but remain Chair of the Board, focusing her operat", "url": "https://www.stocktitan.net/sec-filings/BYSI/8-k-beyond-spring-inc-reports-material-event-e0cfd7a95d7c.html", "source_name": "Stock Titan", "published_at": "2026-06-08T15:10:06", "published_display": "08 Jun 2026 15:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring Announces Major Leadership Transition and New CEO", "summary": "BeyondSpring (BYSI) has announced a significant leadership change, effective July 1, 2026. Founder Dr. Lan Huang will step down as CEO but remain as chair, focusing on SEED Therapeutics, while Min Qiu will take over as the new CEO. The company also appointed Dr. Jiangwen Majeti a", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/2323718/beyondspring-announces-major-leadership-transition-and-new-ceo/", "source_name": "The Globe and Mail", "published_at": "2026-06-08T15:10:06", "published_display": "08 Jun 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BYSI - BeyondSpring Inc Stock Price and Quote", "summary": "This page provides a detailed financial overview and news updates for BeyondSpring Inc. (BYSI), a biotechnology company focused on immuno-oncology cancer therapies. It includes real-time stock quotes, key financial metrics, analyst ratings history, and a compilation of recent pre", "url": "https://finviz.com/stock?t=BYSI", "source_name": "Finviz", "published_at": "2026-06-04T23:40:04", "published_display": "04 Jun 2026 23:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring Elevates Min Qiu to CEO, Names Na Li CFO in Leadership Transition", "summary": "BeyondSpring Inc. has announced a significant leadership transition, appointing Min Qiu as CEO and Na Li as CFO, effective July 1, 2026. Founder Dr. Lan Huang will remain Chairman while focusing on SEED Therapeutics. This restructuring aims to align management with the operationa", "url": "https://www.citybiz.co/article/856096/beyondspring-elevates-min-qiu-to-ceo-names-na-li-cfo-in-leadership-transition/", "source_name": "citybiz", "published_at": "2026-06-04T16:42:27", "published_display": "04 Jun 2026 16:42", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring names new CEO, CFO as founder shifts to chairman role By Investing.com", "summary": "BeyondSpring Inc. has announced a leadership transition effective July 1, 2026, with Min Qiu appointed as CEO and Na Li as CFO. Founder Dr. Lan Huang will move to a Chairman role, while Dr. Jiangwen Majeti becomes Vice Chairman. The company is advancing its Phase 3 trial for Plin", "url": "https://m.za.investing.com/news/stock-market-news/beyondspring-names-new-ceo-cfo-as-founder-shifts-to-chairman-role-93CH-4314171?ampMode=1", "source_name": "Investing.com South Africa", "published_at": "2026-06-04T16:42:27", "published_display": "04 Jun 2026 16:42", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring Inc. Appoints Na Li as Chief Financial Officer, Effective July 1, 2026", "summary": "BeyondSpring Inc. has appointed Ms. Na Li as its new Chief Financial Officer, effective July 1, 2026. Ms. Li brings over two decades of finance leadership experience from the pharmaceutical, biotechnology, and public-company sectors, including previous CFO roles. Her expertise in", "url": "https://www.marketscreener.com/news/beyondspring-inc-appoints-na-li-as-chief-financial-officer-effective-july-1-2026-ce7f5ddcd18cf725", "source_name": "www.marketscreener.com", "published_at": "2026-06-04T13:42:27", "published_display": "04 Jun 2026 13:42", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value", "summary": "BeyondSpring Inc. has announced a significant leadership transition effective July 1, 2026, aimed at focusing on the DUBLIN-4 Phase 3 program for Plinabulin. Dr. Lan Huang will remain Chairman of BeyondSpring while also leading SEED Therapeutics, and Min Qiu has been appointed CE", "url": "https://www.globenewswire.com/news-release/2026/06/04/3306631/0/en/beyondspring-announces-leadership-transition-to-deliver-focused-execution-on-its-confirmatory-dublin-4-program-and-long-term-value.html", "source_name": "GlobeNewswire", "published_at": "2026-06-04T07:00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026", "summary": "BeyondSpring announced updated efficacy and safety data from a Phase 2 study of pembrolizumab plus Plinabulin and docetaxel in metastatic NSCLC patients who progressed after first-line immune checkpoint inhibitor therapy. The study, presented at ASCO 2026, demonstrated durable cl", "url": "https://www.manilatimes.net/2026/06/02/tmt-newswire/globenewswire/beyondspring-presents-the-latest-update-of-a-phase-2-study-demonstrating-durable-clinical-benefit-of-pembrolizumab-plus-plinabulindocetaxel-in-metastatic-nsclc-after-progression-on-first-line-immune-checkpoint-inhibitor-therapy-at-asco-2026/2356639/amp", "source_name": "The Manila Times", "published_at": "2026-06-03T10:39:39", "published_display": "03 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring Presents the Latest Update of a Phase 2 Study", "summary": "BeyondSpring Inc. announced updated efficacy and safety data from an investigator-initiated Phase 2 study of pembrolizumab plus Plinabulin and docetaxel for metastatic non-small cell lung cancer (NSCLC) patients who progressed after first-line immune checkpoint inhibitor therapy.", "url": "https://www.globenewswire.com/news-release/2026/06/02/3304984/0/en/beyondspring-presents-the-latest-update-of-a-phase-2-study-demonstrating-durable-clinical-benefit-of-pembrolizumab-plus-plinabulin-docetaxel-in-metastatic-nsclc-after-progression-o.html", "source_name": "GlobeNewswire", "published_at": "2026-06-02T10:40:37", "published_display": "02 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring (BYSI) Faces Selling Pressure: Support Levels Tested After 2.33% Decline - Point of Control", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxPc1JKRnpMNndtbWJXSXY2QUQ0b25weVhjeUc5TmNNLWFtbXh6STdGTTJsSW5jaWNyWkxKUmhnclV4U3pkdHhKQ3dOa29KTnJNMHJzeV96YXIxSFFLTGQ0NjBmTXN2aUxuNnZnV3VrYk5HVGhNTlNYdTRvM1l2TVRLT0F5VDJESERLcXpKOFlDalJmMVlDMkxheUlsTVV0NnhmR19DcVUyZGR4aXpCdUphSWs5MEkyNW1oZ05jdl93cW0zRF9kZnR6S1JWWnY?oc=5", "source_name": "B\u00f6l\u00fcm Sonu Canavar\u0131", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring (BYSI) Faces Selling Pressure: Support Levels Tested After 2.33% Decline - Insider Buying Alerts", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOZ3BhcWVvR0FxRGFGQ2M0QmVNc2JIWTZDcEduRzFuWWN6N1ozS0gtXzZJQWlVeTJkQ1ZTV1pkWHFHbDFzN3llR0dNaGxDdjMwLWZmbWh3T3lub3ZLeHBGQzIxUDBfN3AyT2xnMkg1WUtMb1FVNjVXcVJuUnVuOXBpOWVsc3VManZsVVNHaUY1eC1haS1UdjRGUHN1WXhxbkVFQWdwUXhBSEhLMjlsQnJOMWlFRm9KMDFmUXM2eEszVm9Hd3J0Z3c?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting", "summary": "BeyondSpring Inc. announced an upcoming poster presentation at the 2026 ASCO Annual Meeting. The presentation will detail Study 303, an investigator-initiated Phase 2 study supported by Merck and BeyondSpring, focusing on a triple combination therapy for metastatic non-small cell", "url": "https://www.globenewswire.com/news-release/2026/05/18/3296480/0/en/beyondspring-announces-poster-presentation-at-2026-asco-annual-meeting.html", "source_name": "GlobeNewswire", "published_at": "2026-05-18T11:10:36", "published_display": "18 May 2026 11:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring shares rise after narrower quarterly loss and pipeline advances (BYSI)", "summary": "", "url": "https://finance.yahoo.com/m/2b6d08a5-dc2e-3913-ac65-dadae08f7898/beyondspring-shares-rise.html", "source_name": "InvestorsHub", "published_at": "2026-05-13T13:29:56+00:00", "published_display": "13 May 2026 13:29", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update", "summary": "", "url": "https://finance.yahoo.com/news/beyondspring-reports-first-quarter-2026-110000960.html", "source_name": "GlobeNewswire", "published_at": "2026-05-13T11:00:00+00:00", "published_display": "13 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/beyondspring-reports-compelling-data-plinabulin-110000913.html", "source_name": "GlobeNewswire", "published_at": "2026-04-22T11:00:00+00:00", "published_display": "22 Apr 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring Inc. Confirms Phase 3 Overall Survival Benefit for Plinabulin in NSCLC and Plans DUBLIN-4 Study", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxOUk1BMjRjZVd5LXc0WG1LZkhiNFNKNlFDS1UzYXc4eXhST012RFB6MWZscWdUQmFxSVM3WF8yT0RuSno4Y1dnLUl3d1pEaUhUc19hQTJGSERoamQ1OS1MYU40UmJQeU9Nd1Z6a0Z1NVQ3N3lOZWpaRmZxNE9UMzlkVFZySWNURXVqTHFHSVRYUTFGLVUzelFqcXd2WTF3MHdWY24zX3pvZnp2YWpCSFctc3E0bHROMzZndXNGS2VtY0gzSGMydUlUQVdRbHNyNzNOckhfa1RGYUM?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BeyondSpring (BYSI) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE9SNWZhalJrT1BFTHpfeVd6QVR5ZFNJblR1QnFnTHFYSGNSczlWTTA2QXhoaWh5cU1mQ25rVjZTY2pQaXhfRUcwcTBWR2xySjNMR2ktOFU0RTdvUQ?oc=5", "source_name": "MarketBeat", "published_at": "2017-04-01T16:56:20+00:00", "published_display": "01 Apr 2017 16:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 88, "total_relevant": 47, "sentiment_summary": {"positive": 9, "negative": 10, "neutral": 28, "score": 52, "total": 47, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 15.4, "count": 28}, {"event": "earnings", "label": "Earnings", "weight": 7.7, "count": 16}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 9, "negative_events": 10}, "market_context": {"has_market_context": true, "latest_close": 1.44, "latest_week": "2026-07-10", "one_week_move": -23.0, "four_week_move": -8.3, "twelve_week_move": -16.8, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.6225, "market_dynamics_buy_signal": false, "relative_strength": -29.806391, "fair_value_gap": -17.0, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 49.1312, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-23.0% over one week, -8.3% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 61, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingKey", "count": 7}, {"label": "Stock Titan", "count": 6}, {"label": "TradingView", "count": 6}, {"label": "Market source", "count": 5}, {"label": "GlobeNewswire", "count": 5}, {"label": "Donan\u0131mHaber", "count": 4}, {"label": "simplywall.st", "count": 2}, {"label": "Investing.com Nigeria", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 39}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 28}, {"label": "Earnings", "count": 16}, {"label": "Regulatory and legal", "count": 1}, {"label": "Deals and strategy", "count": 1}, {"label": "Analyst action", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "39", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-23.0% over one week, -8.3% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "BeyondSpring (BYSI) Q1 2026 Earnings: EPS Loss of -$0.05 Amid No Revenue and Stock Decline - Guidance vs Actual"}], "updated_at": "2026-07-15T23:13:29.443958+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}